Hello everyone,
See the online event and pertinent article.

I have submitted a question about fear of recurrence and the reliability of the $5000.00 Oncotype DX genomic assay to - 

Breast Cancer Trials Q&A Event from 6-7pm, 7 October 2020 (AEDT).
To watch the Q&A, please click on the following link and enter your details:
https://webcast.gigtv.com.au/Mediasite/Play/38c05001e60a46b1b01ecb7d25b8727c1d 
Should you require tech support, please contact: https://www.gigtv.com.au/support/

The following article perhaps sheds some light on why the MSAC did not approve a Medicare rebate for the test. On the one hand, it is not surprising that Oncotype company keeps their total methodology to themselves - but, their opacity resists all efforts to prove their hypothesis.

Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT2-Profiler Multiplex RT-PCR

https://www.nature.com/articles/s41598-019-56910-0

"In the Cancer Biology Reproducibility Study the Errington group justifiably demands that retesting a hypothesis with the same or a closely related methodology should provide the same evidence that in turn enables the investigator to converge on an explanation for the finding that is not dependent on either methodology3. This inter-assay reproducibility was obviously not fulfilled for the Oncotype DX in comparison to the RT2-Profiler assay, which is due to the fact that the Oncotype DX assay remains a black box. Several parameters are not reported at all, while other parameters are reported in a way that differs from all claims in the original publication and the patent files available for the assay (International Patent Publication Numbers WO2006/052862A1 and WO2014/130617A1), as shown in the results."